Paclitaxel, Cisplatin, and Camrelizumab Regimen

Paclitaxel: 175 mg/m², administered by intravenous infusion on day 1 of each cycle and every 3 weeks for two cycles (Q3W).
Cisplatin: 75 mg/m², administered by intravenous infusion on day 1 of each cycle and every 3 weeks for two cycles (Q3W).
Camrelizumab: 200 mg, administered by intravenous infusion on day 1 of each cycle and every 3 weeks for one cycle (Q3W), for a total of two cycles.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Chen M., Huang Y., Zhang S., Zheng Y., Zeng T., Chen C, & Zheng B. (2024). Camrelizumab in combination with chemotherapy versus concurrent chemoradiotherapy for the conversion of locally advanced unresectable oesophageal squamous carcinoma: protocol for a two-arm, open-label phase II trial. BMJ Open, 14(2), e075421.

Publication 2024

Corresponding Organization : Union Hospital

Top 5 similar protocols

Variable analysis

independent variables

Paclitaxel: 175 mg/m^2, administered by intravenous infusion on day 1 of each cycle and every 3 weeks for two cycles (Q3W)
Cisplatin: 75 mg/m^2, administered by intravenous infusion on day 1 of each cycle and every 3 weeks for two cycles (Q3W)
Camrelizumab: 200 mg, administered by intravenous infusion on day 1 of each cycle and every 3 weeks for one cycle (Q3W), for a total of two cycles

dependent variables

Not explicitly mentioned

control variables

Not explicitly mentioned

controls

No positive or negative controls specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!